新光药业(300519) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 101,895,419.99, representing a 6.01% increase compared to CNY 96,123,097.26 in the same period last year[3]. - Net profit attributable to shareholders was CNY 42,819,141.85, up 9.85% from CNY 38,981,195.06 year-on-year[3]. - The basic earnings per share increased by 12.50% to CNY 0.27 from CNY 0.24 in the previous year[3]. - The total operating revenue for the first quarter of 2022 was CNY 101,895,419.99, an increase from CNY 96,123,097.26 in the previous period[19]. - The operating profit for the quarter was CNY 50,323,415.18, up from CNY 45,867,233.88, reflecting an increase of approximately 10%[20]. - The company reported a total comprehensive income of CNY 43,025,693.97, compared to CNY 39,104,856.91 in the previous year, indicating a growth of approximately 10.4%[21]. - The net profit attributable to the parent company was CNY 42,819,141.85, an increase from CNY 38,981,195.06 in the previous year, representing a growth of approximately 4.7%[21]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 979,092,999.45, a 5.01% increase from CNY 932,403,805.04 at the end of the previous year[3]. - The total liabilities at the end of the first quarter were CNY 89,850,234.13, compared to CNY 86,186,733.69 at the beginning of the year[17]. - The total equity attributable to the owners of the parent company was CNY 889,242,765.32, up from CNY 846,217,071.35 at the beginning of the year[17]. Cash Flow - Cash flow from operating activities showed a net increase of 5.21%, totaling CNY 59,363,672.75 compared to CNY 56,425,426.74 in the same period last year[3]. - The net cash flow from operating activities was CNY 59,363,672.75, compared to CNY 56,425,426.74 in the previous year, showing an increase of approximately 3.4%[24]. - The cash inflow from investment activities increased by 566.33% to CNY 100,639,743.48, primarily due to the redemption of financial products[7]. - The total cash inflow from investment activities was CNY 100,639,743.48, significantly higher than CNY 15,103,561.64 in the previous year, indicating a substantial increase[24]. - The net cash flow from investment activities was -CNY 43,926,593.82, an improvement from -CNY 75,136,324.86 in the previous year, showing a reduction in cash outflow by approximately 41.5%[25]. Investments and Expenses - The company reported a significant increase in investment income, which rose by 517.74% to CNY 603,531.59 from CNY 97,699.66 in the previous year[6]. - Research and development expenses rose to CNY 3,966,483.95 from CNY 3,397,403.34, marking an increase of about 16.7%[20]. - The total operating costs for the first quarter of 2022 amounted to CNY 52,906,632.17, compared to CNY 51,049,564.54 in the previous period[19]. Other Financial Metrics - The company experienced a 28.00% increase in trading financial assets, amounting to CNY 160,000,000.00, up from CNY 125,000,000.00[6]. - The company’s contract liabilities surged by 2697.76% to CNY 2,460,347.29, indicating a significant increase in advance payments received[6]. - The cash and cash equivalents at the end of the first quarter were CNY 609,104,874.84, up from CNY 593,667,795.91 at the beginning of the year[15]. - The cash and cash equivalents at the end of the period totaled CNY 609,104,874.84, up from CNY 573,136,890.10, representing an increase of about 6.3%[25]. - The inventory at the end of the first quarter was CNY 43,799,885.72, down from CNY 46,761,586.25 at the beginning of the year[15]. - The accounts receivable decreased to CNY 9,777,781.20 from CNY 15,922,855.68 at the beginning of the year[15]. - The company reported a significant increase in prepayments, rising to CNY 3,556,281.70 from CNY 2,397,787.40 at the beginning of the year[15]. Market and Product Development - The company has not disclosed any new product developments or market expansion strategies in this report[14].